Logo

American Heart Association

  2
  0


Final ID: MDP1535

Lipid Trends of Adults Who Participate in Hybrid Cardiac Rehabilitation

Abstract Body (Do not enter title and authors here): Background
Hybrid cardiac rehabilitation (HCR) is an emerging approach to increase participation in cardiac rehabilitation, which targets improvements in functional status and broader risk factor modification including lipid management. However, long-term lipid control trends of patients engaging in HCR remain unexplored.

Methods
Using data from a quality improvement program initiated during COVID-19, we conducted a retrospective analysis of 68 adults eligible for HCR from Jan 2021 to Feb 2023 at the Johns Hopkins Health System (Baltimore, MD), utilizing the Corrie digital health platform. This multi-component platform combines expert knowledge with gamified education and virtual coaching to deliver HCR. Patients hospitalized for cardiovascular events qualifying for HCR were recruited for a pilot study of a randomized controlled trial (mTECH REHAB; NCT05238103). We modeled trends in low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and triglycerides via mixed-effects regression.

Results
Among 68 eligible adults, 41 participated in HCR, with a mean age of 60.1 years, 78.1% male, 24.3% Black, and 14.6% Asian/Mixed. HCR participation was significantly associated with being married (61% vs 33%, p=0.044) or employed (63% vs 26%, p=0.015). On average, 2.3 lipid panels were assessed per person over a median of 12 months (max 30 months) post-discharge. During this period, LDL-C levels decreased from 84.6 mg/dL (95% CI: 75.0-94.1) to 53.0 mg/dL (95% CI: 34.3-71.8) (p for trend = 0.003). Non-HDL-C decreased from 105.9 mg/dL (95% CI: 95.7-116.1) to 74.2 mg/dL (95% CI: 54.1-94.3) (p for trend = 0.005). Levels of HDL-C and triglycerides showed no significant changes (p for trend = 0.724 and 0.607). Among 34 participants with ≥2 lipid panels, the proportion of LDL-C <70 mg/dL increased from 41.2% at hospitalization to 64.7% at the most recent check, and LDL-C <55 mg/dL increased from 14.7% to 38.2%.

Conclusion
Improvements in atherogenic lipid levels, in particular LDL-C and non-HDL-C, were observed in adults participating in HCR after a cardiovascular event. Our findings highlight the potential of HCR to support optimal lipid management in adults with cardiovascular disease.
  • Gao, Yumin  ( Georgetown University School of Medicine , Baltimore , Maryland , United States )
  • Nimbalkar, Mansi  ( Johns Hopkins School of Medicine , Baltimore , Maryland , United States )
  • Desai, Anushka  ( Georgetown University School of Medicine , Washington DC , District of Columbia , United States )
  • Mathews, Lena  ( Johns Hopkins School of Medicine , Baltimore , Maryland , United States )
  • Marvel, Francoise  ( Johns Hopkins School of Medicine , Baltimore , Maryland , United States )
  • Garcia-garcia, Hector  ( MedStar , Washington , District of Columbia , United States )
  • Martin, Seth  ( Johns Hopkins School of Medicine , Baltimore , Maryland , United States )
  • Ding, Jie  ( Johns Hopkins School of Medicine , Baltimore , Maryland , United States )
  • Kim, Chang  ( Johns Hopkins School of Medicine , Baltimore , Maryland , United States )
  • Spaulding, Erin  ( Johns Hopkins School of Nursing , Baltimore , Maryland , United States )
  • Isakadze, Nino  ( Johns Hopkins School of Medicine , Baltimore , Maryland , United States )
  • Stewart, Kerry  ( Johns Hopkins University , Owings Mills , Maryland , United States )
  • Broderick, Ashley  ( Johns Hopkins School of Medicine , Baltimore , Maryland , United States )
  • Bush, Alexandra  ( Johns Hopkins School of Medicine , Baltimore , Maryland , United States )
  • Macfarlane, Zane  ( Perelman School of Medicine at the University of Pennsylvania , Philadelphia , Pennsylvania , United States )
  • Author Disclosures:
    Yumin Gao: DO NOT have relevant financial relationships | Mansi Nimbalkar: DO NOT have relevant financial relationships | Anushka Desai: DO NOT have relevant financial relationships | Lena Mathews: DO NOT have relevant financial relationships | Francoise Marvel: DO have relevant financial relationships ; Ownership Interest:Corrie Health:Active (exists now) ; Consultant:Kaneka:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Consultant:Apple:Active (exists now) | Hector Garcia-Garcia: No Answer | Seth Martin: DO have relevant financial relationships ; Ownership Interest:Corrie Health:Active (exists now) ; Consultant:89bio:Past (completed) ; Consultant:Sanofi:Past (completed) ; Consultant:Premier:Past (completed) ; Consultant:Novo Nordisk:Past (completed) ; Consultant:Novartis:Past (completed) ; Consultant:NewAmsterdam:Past (completed) ; Consultant:Kaneka:Past (completed) ; Consultant:Chroma:Past (completed) ; Consultant:BMS:Past (completed) ; Consultant:AstraZeneca:Past (completed) ; Consultant:Amgen:Past (completed) ; Research Funding (PI or named investigator):Merck:Active (exists now) ; Research Funding (PI or named investigator):Apple:Active (exists now) ; Research Funding (PI or named investigator):Google:Active (exists now) | Jie Ding: DO NOT have relevant financial relationships | Chang Kim: DO NOT have relevant financial relationships | Erin Spaulding: DO have relevant financial relationships ; Consultant:Corrie Health:Active (exists now) | Nino Isakadze: DO NOT have relevant financial relationships | Kerry Stewart: DO NOT have relevant financial relationships | Ashley Broderick: DO NOT have relevant financial relationships | Alexandra Bush: DO NOT have relevant financial relationships | Zane MacFarlane: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Out of Office: Health Technology in the Community

Monday, 11/18/2024 , 12:50PM - 02:05PM

Moderated Digital Poster Session

More abstracts on this topic:
12,13-diHOME Attenuates Pro-Arrhythmic Effect of High-Fat Diet

Buck Benjamin, Baer Lisa, Deschenes Isabelle, Chinthalapudi Krishna, Gallego-perez Daniel, Stanford Kristin, Hund Thomas, Areiza Natalia, Xu Xianyao, Elliott Austin, Wan Xiaoping, Nassal Drew, Lane Cemantha, Nirengi Shinsuke, James Natasha Maria

ALPACAR Phase 2 Trial of Zerlasiran: Multiple doses of a Small-Interfering RNA Targeting Lipoprotein(a) with 60 weeks Folow Up.

Nissen Steven, Dorresteijn Jannick, Fok Henry, Rider David, Romano Steve, Wolski Kathy, Rambaran Curtis, Wang Qiuqing, Nicholls Stephen, Navar Ann Marie, Ray Kausik, Schwartz Gregory, Szarek Michael, Stroes Erik, Troquay Roland

More abstracts from these authors:
AI Everywhere

Albert David, Turakhia Mintu, Martin Seth, Mault James, Isakadze Nino

Impact of Technology-Enabled Home-Based Cardiac Rehabilitation on Functional Status and Cardiovascular Health Metrics: The American Heart Association Health Technology Network mTECH-Rehab Randomized Controlled Trial

Kim Chang, Zhang Xinyi, Sheng Qicong, Macfarlane Zane, Gao Yumin, Broderick Ashley, Bush Alexandra, Gallagher Jeanmarie, Harp Meghan, Benjamin Preeti, Neigh Brittany, Nimbalkar Mansi, Lobien Jackie, Reddy Tara, Burley Tanya, Jackson Keith, Lee Matthias, Sham Jeffrey, Molello Nancy, Commodore-mensah Yvonne, Stewart Kerry, Spaulding Erin, Ding Jie, Hanley Daniel, Mcbee Nichol, Michos Erin, Marvel Francoise, Martin Seth, Mathews Lena, Isakadze Nino, Weinstein Robert, Hussain Zaib, Kassamali Ali, Zhao Henry, Rayani Asma

You have to be authorized to contact abstract author. Please, Login
Not Available